|
| Press Releases |
|
 |
|
| Friday, July 12, 2024 |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「LEQEMBI」（レカネマブ）が香港においてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性 アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（香港製品名：「樂意保(R)」、一般名：レカネマブ）について、香港衛生署（Department of Health）より新薬承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
|
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 |
| エーザイ株式会社とバイオジェン・インクは、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（一般名：レカネマブ）について、静注（IV）維持投与に関する生物製剤承認一部変更申請（sBLA）が米国食品医薬品局（FDA）に受理されたことをお知らせします。 more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Droid Investment Funds Launches 'The 10 Fund Competition Institutional Capital vs. The Wisdom of the Crowd'
Apr 8, 2026 17:38 HKT/SGT
|
|
|
Guoyuan International: Essex Bio-Technology Embarks on Global Expansion, Maintains BUY Rating with Target Price of HK$6.84
Apr 8, 2026 17:20 HKT/SGT
|
|
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30: JST
|
|
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30 HKT/SGT
|
|
|
正力新能2025年度業績實現爆發式增長 淨利潤增幅近8倍
Apr 8, 2026 11:44 HKT/SGT
|
|
|
三菱重工、NEDO懸賞金活用型プログラム「GENIAC-PRIZE」で第2位を受賞
Apr 8, 2026 11:30: JST
|
|
|
三菱重工グループのCrystal Mover Services、米国アトランタ国際空港のAPMシステム「ATL SkyTrain」の設備更新工事を受注
Apr 8, 2026 11:30: JST
|
|
|
MHI and Algomatic Win Second Place in the NEDO GENIAC‑PRIZE Program
Apr 8, 2026 12:03 JST
|
|
|
Heavyweight Endorsement from Top-tier Cornerstone Investors! Sigenergy (06656.HK) Launches IPO: Led by Temasek and Goldman Sachs, the AI Energy Storage Leader Ignites Hong Kong's New Stock Frenzy
Apr 8, 2026 11:01: JST
|
|
|
Heavyweight Endorsement from Top-tier Cornerstone Investors! Sigenergy (06656.HK) Launches IPO: Led by Temasek and Goldman Sachs, the AI Energy Storage Leader Ignites Hong Kong's New Stock Frenzy
Apr 8, 2026 10:01 HKT/SGT
|
|
|
頂級基石陣容重磅背書！思格新能源（06656.HK）啟動招股：淡馬錫、高盛領銜，AI 儲能領頭羊點燃港股新股熱潮
Apr 8, 2026 10:01 HKT/SGT
|
|
|
首程控股（0697.HK）分紅回購並舉 8年累計回饋股東約68.77億港元
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Shoucheng Holdings (0697.HK) Combines Dividends and Share Buybacks in Tandem, Returning Approximately HK$6.877 Billion to Shareholders Over Eight Years
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Formerra宣佈全球提價
Apr 8, 2026 04:00 HKT/SGT
|
|
|
Formerra宣布全球提价
Apr 8, 2026 04:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
